MarginsXMarginsX
Home › Markets › Health Care › ACET

Adicet Bio Inc. (ACET)

ACET trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.75
-1.08% on the day
Market cap
$25.7M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerACET on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001720580
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
4.1 months
$27.1M cash at September 30, 2026
Share count, 1 year
-2.3%
2025-11-03 to 2026-11-03 · +247.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
$5.9M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern."
10-Q 2026-11-05
Cash and burn$27.1M cash; operating cash flow -$20.0M a quarter.Report 2026-09-30
Shares outstanding9,361,596 (2026-11-03); 153,255,581 a year earlier; 43,164,522 three years earlier. 1y figure adjusted for splits (1-for-16 overall); 3y figure adjusted for splits (1-for-16 overall).Cover page 2026-11-03
Reverse splits, 3 years1; latest 1-for-16 on 2025-12-30Source 2025-12-30
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $6.6M, sold $675K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$18.9M-$17.9M$27.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$21.4M-$19.8M$33.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$20.2M-$21.5M$36.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$30.5M-$20.9M$38.9MNo debt tagsNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$26.9M-$22.3M$29.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$31.2M-$26.6M$34.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$28.2M-$25.4M$28.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$28.7M-$24.1M$56.5MNo debt tagsNeeds four quarters10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-03-12
Latest annual report10-K/A2026-05-20
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 683 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.9%
1 month-45.6%
3 months-66.3%
Year to date-67.0%
1 year-73.8%
From 52-week high-73.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M
ABVCABVC BioPharma Inc.$0.9400+3.30%$25.4M
CRVOCervoMed Inc.$1.67-1.18%$25.3M
IMMPImmutep Limited$3.40-2.30%$25.1M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M
IXHLIncannex Healthcare Inc.$1.93-2.03%$24.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier